Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. (Q44555759)

4 December 2017

title

Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. (English)

1 reference

4 December 2017

1 reference

1 reference

Larry J Copeland

1

1 reference

4 December 2017

Michael Bookman

series ordinal

2

1 reference

4 December 2017

Edward Trimble

series ordinal

3

1 reference

4 December 2017

Gynecologic Oncology Group Protocol GOG 182-ICON5

series ordinal

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

90

1 reference

4 December 2017

issue

2 Pt 2

1 reference

4 December 2017

page(s)

S1-7

1 reference

Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900337-8

7 January 2021

10.1016/S0090-8258(03)00337-8

Identifiers

DOI

1 reference

4 December 2017

1 reference